Arvinas to Present Vepdegestrant Posters at 2024 ESMO Breast Cancer Congress

On May 9, 2024, Arvinas, Inc. (Nasdaq: ARVN) revealed its plans to showcase two posters featuring updated clinical trial data for vepdegestrant at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress. The event is scheduled to take place from May 15-17, 2024, in Berlin, Germany. Vepdegestrant is a pioneering investigational PROTAC® estrogen receptor (ER) degrader currently under joint development by Arvinas and Pfizer. It aims to treat patients with early, locally advanced, or metastatic ER positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) breast cancer.

The first poster session is set for Thursday, May 16, 2024, from 12:00 to 1:00 p.m. CET/6:00 to 7:00 a.m. ET. This session falls under the category of Metastatic Breast Cancer. The specific poster titled "Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: updated phase 1b cohort results" is identified as Poster 218P. The abstract for this presentation is numbered 453.

Another important poster titled "TACTIVE-K: phase 1b/2 study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer" will also be featured. This poster, numbered 264, is part of a Trial-in-Progress (TiP) presentation and is abstract number 488. Abstracts for these sessions are available on the official ESMO Breast Cancer Annual Congress website.

Vepdegestrant is an investigational, orally bioavailable PROTAC protein degrader designed to target and degrade the estrogen receptor (ER). This innovation is intended for treating patients with ER positive (ER+)/human epidermal growth factor receptor 2 negative (ER+/HER2-) breast cancer. It is being developed both as a potential monotherapy and in combination therapies across various treatment settings for ER+/HER2- metastatic breast cancer.

In July 2021, Arvinas entered into a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant. This partnership involves shared worldwide development costs, commercialization expenses, and profits between the two companies. Notably, the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to vepdegestrant as a monotherapy for treating adults with ER+/HER2- locally advanced or metastatic breast cancer who have previously undergone endocrine-based therapy.

Arvinas is a clinical-stage biotechnology firm focused on enhancing the lives of patients afflicted with debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Utilizing its proprietary PROTAC® Discovery Engine platform, Arvinas engineers proteolysis targeting chimeras (PROTAC® targeted protein degraders) that leverage the body's natural protein disposal system to selectively and efficiently degrade and eliminate disease-causing proteins. Besides its robust preclinical pipeline targeting both validated and "undruggable" proteins, Arvinas has four investigational clinical-stage programs. These include vepdegestrant for locally advanced or metastatic ER+/HER2- breast cancer, ARV-766 and bavdegalutamide for metastatic castration-resistant prostate cancer, and ARV-102 for neurodegenerative disorders.